New hope for bleeding risk in hepatitis b patients?
NCT ID NCT03664518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eltrombopag
- What this could lead to
- If successful, this could offer a treatment option for low platelet counts in people with chronic hepatitis B, reducing bleeding risk.
- What could go wrong
- This is a small, single-arm phase 2 trial with no placebo group, so results are preliminary. Eltrombopag may cause liver issues or blood clots, and it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Double attack on blood disorder: could two drugs beat one for stubborn ITP?
- Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
- New hope for lupus patients with dangerous low platelet counts
- New shot aims to boost platelets in bleeding disorder
- New drug IASO-782 aims to tame immune attacks on blood cells